By Benjamin Horney (May 15, 2017, 5:49 PM EDT) -- Advent International Corp. and Shanghai Pharmaceuticals Holding Co. Ltd. may make an offer for German pharmaceutical company Stada Arzneimittel AG, Bloomberg reported Monday. The report comes about a month after Bain Capital and Cinven inked a €5.3 billion ($5.6 billion) buyout of Stada, meaning a bidding battle may be about to begin. According to the report, Boston-based private equity firm Advent and Shanghai Pharmaceuticals are weighing a proposal worth about €70 per share, which would make the deal worth more than the €66-per-share agreement inked by Bain and Cinven. It is possible Advent and Shanghai Pharmaceuticals decide not to make the competing offer, the report noted. A separate Monday report from Reuters, however, disputed Bloomberg's report, saying the duo has not approached Stada about making a counteroffer....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
